<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730314</url>
  </required_header>
  <id_info>
    <org_study_id>CCI #07-00119</org_study_id>
    <secondary_id>CHLA-#07-00119</secondary_id>
    <nct_id>NCT00730314</nct_id>
  </id_info>
  <brief_title>Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells</brief_title>
  <official_title>Phase I/II Trial Of Hematopoietic Stem Cell Transplant (HSCT) For Children With A Genetic Disease Of Blood Cells Without An HLA-Matched Sibling Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical trial of bone marrow transplantation for patients with the diagnosis of a
      genetic disease of blood cells that do not have an HLA-matched sibling donor. Genetic
      diseases of blood cell include: Red blood cell defects e.g. hemoglobinopathies (sickle cell
      disease and thalassemia), Blackfan-Diamond anemia and congenital or chronic hemolytic
      anemias; White blood cells defects/immune deficiencies e.g. chronic granulomatous disease,
      Wiskott-Aldrich syndrome,Osteopetrosis, Kostmann's syndrome (congenital neutropenia),
      Hereditary Lymphohistiocytosis (HLH); Platelets defects e.g.Congenital amegakaryocytic
      thrombocytopenia; Metabolic/storage disorders e.g. leukodystrophies,mucopolysaccharidoses as
      Hurler disease;Stem cell defects e.g.reticular agenesis, among many other rare similar
      conditions.

      The study treatment plan uses a new transplant treatment regimen that aims to try to decrease
      the acute toxicities and complications associated with the standard treatment plans and to
      improve outcome

      The blood stem cells will be derived from either unrelated donor or unrelated umbilical cord
      blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with
      the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling
      donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated
      umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan,
      Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a
      MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to
      hematopoietic stem cell transplant (HSCT).

      It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities
      associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal
      obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of
      fludarabine to a conditioning regimen with myeloablative doses of Busulfan and reduced
      dosages of Cytoxan prior to HSCT will overcome the engraftment barrier posed by an intact
      immune system, which is seen in patients with a genetic disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicities</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>engraftment</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>immune reconstitution</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall and event free survival survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Thalassemia</condition>
  <condition>Anemia</condition>
  <condition>Granuloma</condition>
  <condition>Wiskott-Aldrich Syndrome</condition>
  <condition>Chediak Higashi Syndrome</condition>
  <condition>Osteopetrosis</condition>
  <condition>Neutropenia</condition>
  <condition>Thrombocytopenia</condition>
  <condition>Hurler Disease</condition>
  <condition>Niemann-Pick Disease</condition>
  <condition>Fucosidosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Unrelated donor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cord Blood</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic stem cell transplantation</intervention_name>
    <description>hematopoietic stem cell transplantation conditioning regimen depending on graft source</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lethal or sublethal genetic disease of blood cells, who lack a fully histocompatible
             sibling or other family donor

          -  Genetic diseases that would be candidates for this protocol includes those that have
             been shown to benefit from allogeneic HSCT: Red blood cell defects, Leukocyte defects/
             Primary immune deficiencies, Platelets defects, Metabolic/storage disorders and Stem
             cell defects.

          -  Renal: creatinine clearance or glomerular filtration rate (GFR) ≥50 ml/min/1.73m2 and
             not requiring dialysis.

          -  Pulmonary: FEV1, FVC and DLCO (corrected for hemoglobin) ≥ 50% predicted. if unable to
             perform pulmonary function tests, then O2 saturation ≥ 92% in room air.

          -  Cardiac: Left ventricular ejection fraction at rest must be ≥ 40%, or shortening
             fraction ≥ 26%

          -  Hepatic: Bilirubin ≤3x upper limit of normal (ULN) and ALT and AST ≤ 5x for age (with
             the exception of isolated hyperbilirubinemia due to Gilbert's syndrome).

          -  Patients will be 0-21 years of age.

          -  Disease specific inclusion criteria (as applicable per protocol).

        Exclusion Criteria:

          -  Recipients should not have any of the general exclusion criteria, and disease specific
             exclusion criteria when applicable.

          -  Patient with histocompatible sibling

          -  End-organ failure that precludes the ability to tolerate the transplant procedure,
             including the conditioning regimen.

          -  Creatinine clearance or GFR &lt; 50 ml/min/1.73m2 or renal failure requiring dialysis.

          -  Congenital heart disease resulting in congestive heart failure.

          -  Severe residual CNS disease/impairment [(other than hemiplegia alone) e.g. coma or
             intractable seizures]

          -  Ventilatory failure

          -  Major congenital anomalies that adversely affect survival, e.g. CNS malformations

          -  Lansky score &lt; 40% or Karnofsky score &lt; 60%

          -  HIV seropositivity

          -  Diagnosis of Fanconi's anemia, Severe Combined Immunodeficiency (SCID)

          -  Positive pregnancy test (For female patients in child bearing period)

          -  Uncontrolled bacterial, viral, or fungal infections (currently taking medication yet
             clinical symptoms progress)

          -  Disease specific exclusion criteria (as applicable per protocol).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hisham Abdel-Azim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Childrens Hospital Los Angeles, University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.childrenshospitalla.org</url>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>June 21, 2016</last_update_submitted>
  <last_update_submitted_qc>June 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Hisham Abdel-Azim</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>unrelated</keyword>
  <keyword>BMT</keyword>
  <keyword>HSCT</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>sickle cell disease</keyword>
  <keyword>thalassemia</keyword>
  <keyword>CGD</keyword>
  <keyword>HLH</keyword>
  <keyword>Blackfan-Diamond anemia</keyword>
  <keyword>Hurler</keyword>
  <keyword>leukodystrophy</keyword>
  <keyword>LAD I</keyword>
  <keyword>Genetic diseases</keyword>
  <keyword>Red blood cell defects</keyword>
  <keyword>Leukocyte defects and immune deficiencies</keyword>
  <keyword>Hereditary Lymphohistiocytosis</keyword>
  <keyword>chronic granulomatous disease</keyword>
  <keyword>Wiskott-Aldrich syndrome</keyword>
  <keyword>Chediak Higashi syndrome</keyword>
  <keyword>CD40 ligand deficiency</keyword>
  <keyword>Hyper IgM syndrome</keyword>
  <keyword>leucocytes adhesion defect type 1</keyword>
  <keyword>Osteopetrosis</keyword>
  <keyword>congenital neutropenia</keyword>
  <keyword>X-linked lymphoproliferative disease</keyword>
  <keyword>Platelets defects</keyword>
  <keyword>Congenital amegakaryocytic thrombocytopenia</keyword>
  <keyword>Metabolic and storage disorders</keyword>
  <keyword>Hurler disease</keyword>
  <keyword>leukodystrophies</keyword>
  <keyword>Niemann-Pick disease</keyword>
  <keyword>Fucosidosis</keyword>
  <keyword>Stem cell defects</keyword>
  <keyword>reticular agenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Granuloma</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Wiskott-Aldrich Syndrome</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
    <mesh_term>Osteopetrosis</mesh_term>
    <mesh_term>Chediak-Higashi Syndrome</mesh_term>
    <mesh_term>Fucosidosis</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

